Video

Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC

Author(s):

Axel Grothey, MD

Axel Grothey, MD, medical oncologist at Mayo Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with microsatellite instability-high colorectal cancer (CRC).

Axel Grothey, MD, medical oncologist at Mayo Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with microsatellite instability-high colorectal cancer (CRC).

Related Videos
Grzegorz S. Nowakowski, MD
John Seymour, MBBS, FRACP, PhD
Sagar Lonial, MD, FACP
Sandip P. Patel, MD
Bradley McGregor, MD, director, clinical research, Lank Center for Genitourinary Oncology, Marra Lochiatto Investigator, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Moshe Ornstein, MD, MA, medical oncologist, Department of Hematology and Medical Oncology, Cleveland Clinic
Reid Merryman, MD
Partow Kebriaei, MD
John K. Lee, MD, PhD
Jean L. Koff, MD, MS
Related Content
FDA
September 5th 2024

FDA Awards Orphan Drug Designation to ABD-147 for Neuroendocrine Carcinoma

Oncology Unplugged
August 21st 2024

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

FDA
September 5th 2024

FDA Grants Orphan Drug Designation to Certepetide in Cholangiocarcinoma

Heinz-Josef Lenz, MD, FACP, about the prognostic and predictive value of HER2 gene expression for patients with KRAS wild-type metastatic colorectal cancer (mCRC). Lenz is a professor in the Department of Medicine and the Department of Preventive Medicine in the Division of Oncology at the University of Southern California (USC) Keck School of Medicine in Los Angeles. He also serves as the associate director of Clinical Research, chair of the Gastrointestinal Oncology Program, and co-director of the Colorectal Center at the USC Norris Comprehensive Cancer Center
June 3rd 2024

Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC

OncLive’s August Roundup of Key FDA Approvals in Oncology
September 4th 2024

OncLive’s August Roundup of Key FDA Approvals in Oncology

Arvind Dasari, MD, MS, associate professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center
September 1st 2024

Targeted Therapy, Vaccines, and Second-Generation Checkpoint Inhibitors Seek to Redefine mCRC Treatment